Biocon: Company Aims to Use Entire Free Cash Flow for Reducing Debt, Anticipating Net Debt to Stay Between $1.1 Billion and $1.2 Billion. FY27-FY28 Outlook Shows Growth Expected in Later Year Due to Multiple New Product Launches.

 11 May 2026 08:31 AM

Biocon: Company Aims to Use Entire Free Cash Flow for Reducing Debt, Anticipating Net Debt to Stay Between $1.1 Billion and $1.2 Billion. FY27-FY28 Outlook Shows Growth Expected in Later Year Due to Multiple New Product Launches.

Biocon: Company Anticipates Growth For Biosimilar Aspart In Second Half Of FY27, Leveraging Full Market Share In Certain US Closed-Door Networks.

 11 May 2026 08:31 AM

Biocon: Company Anticipates Growth For Biosimilar Aspart In Second Half Of FY27, Leveraging Full Market Share In Certain US Closed-Door Networks.

Biocon: Company Aims to Boost Profitability in Generics as New Products Stabilize and Utilization Rises, Plus Focus on Execution for CRDMO Business Syngene.

 11 May 2026 08:31 AM

Biocon: Company Aims to Boost Profitability in Generics as New Products Stabilize and Utilization Rises, Plus Focus on Execution for CRDMO Business Syngene.

Biocon: Co Approved Acquiring ~2% Stake In Biocon Biologics From Employees/other Shareholders Via Issuance Of Up To 87.9 Lakh Shares At ₹376.16 Each (≈₹330.7 Crore) Through A Preferential Allotment, Subject To Approvals, To Consolidate Ownership In Its Subsidiary.

 08 May 2026 07:52 AM

Biocon: Co Approved Acquiring ~2% Stake In Biocon Biologics From Employees/other Shareholders Via Issuance Of Up To 87.9 Lakh Shares At ₹376.16 Each (≈₹330.7 Crore) Through A Preferential Allotment, Subject To Approvals, To Consolidate Ownership In Its Subsidiary.

BIOCON: Q4 CONS NET PROFIT 1.26B RUPEES VS 3.4B (YOY) || Q4 REVENUE 45.2B RUPEES VS 44.2B (YOY)

 08 May 2026 07:49 AM

BIOCON: Q4 CONS NET PROFIT 1.26B RUPEES VS 3.4B (YOY) || Q4 REVENUE 45.2B RUPEES VS 44.2B (YOY)

BIOCON: Q4 EBITDA 10.2B RUPEES VS 10.8B (YOY) || Q4 EBITDA MARGIN 22.59% VS 24.41% (YOY)

 08 May 2026 07:49 AM

BIOCON: Q4 EBITDA 10.2B RUPEES VS 10.8B (YOY) || Q4 EBITDA MARGIN 22.59% VS 24.41% (YOY)

Biocon: Kiran Mazumdar-Shaw Names Niece Claire Mazumdaar As Her Successor. - RTRS Citing Fortune India.

 05 May 2026 09:50 AM

Biocon: Kiran Mazumdar-Shaw Names Niece Claire Mazumdaar As Her Successor. - RTRS Citing Fortune India.

Biocon: Company Anticipates Margin Pressure for Insulin Glargine - NDTV

 05 May 2026 09:38 AM

Biocon: Company Anticipates Margin Pressure for Insulin Glargine - NDTV

Biocon: U.S. FDA Finishes Pre-License Review At Biocon's Bengaluru Biosimilars Plant; Notes 5 Procedural Observations But No Data Issues Found.

 30 Apr 2026 09:15 AM

Biocon: U.S. FDA Finishes Pre-License Review At Biocon's Bengaluru Biosimilars Plant; Notes 5 Procedural Observations But No Data Issues Found.

Biocon: Co. Receives Health Canada Approval For Biosimilars Bosaya And Vevzuo, Expected To Help Over 2 Million Adults With Osteoporosis And Hundreds With Bone Metastases

 21 Apr 2026 08:47 AM

Biocon: Co. Receives Health Canada Approval For Biosimilars Bosaya And Vevzuo, Expected To Help Over 2 Million Adults With Osteoporosis And Hundreds With Bone Metastases

Biocon: HSBC on Biocon Buy with Target Price ₹425 as debt reduction and simplified structure create strong growth foundation, with execution of new biosimilar launches, improving profitability and cash flows, and market share gains in biosimilars as key catalysts.

 20 Apr 2026 09:03 AM

Biocon: HSBC on Biocon Buy with Target Price ₹425 as debt reduction and simplified structure create strong growth foundation, with execution of new biosimilar launches, improving profitability and cash flows, and market share gains in biosimilars as key catalysts.

Biocon: Company Announces U.S. Launch Of Bosaya™ And Aukelso™ Denosumab Biosimilars

 07 Apr 2026 05:23 PM

Biocon: Company Announces U.S. Launch Of Bosaya™ And Aukelso™ Denosumab Biosimilars

Biocon: Company’s Arm Receives FDA Approval For Liraglutide Injection (Gvictoza®) To Treat Type 2 Diabetes, Boosting Its Complex Drug Offerings

 12 Mar 2026 09:19 PM

Biocon: Company’s Arm Receives FDA Approval For Liraglutide Injection (Gvictoza®) To Treat Type 2 Diabetes, Boosting Its Complex Drug Offerings

Biocon: FDA Reduces Rules For Drug Companies Making Cheaper Versions Of Expensive Biologic Drugs.

 09 Mar 2026 02:47 PM

Biocon: FDA Reduces Rules For Drug Companies Making Cheaper Versions Of Expensive Biologic Drugs.

Biocon: Jefferies on Biocon Hold, Target Price Rs 360

 05 Mar 2026 09:04 AM

Biocon: Jefferies on Biocon Hold, Target Price Rs 360

Biocon: Company Invests 315 Crores in Biocon Biosphere and Biocon Pharma Using OCRPS

 04 Mar 2026 07:02 AM

Biocon: Company Invests 315 Crores in Biocon Biosphere and Biocon Pharma Using OCRPS

Biocon: Gets U.S. Approval For Weight Loss Drug Liraglutide, With Market Potential Estimated At $127 Million By December 2025

 24 Feb 2026 09:11 PM

Biocon: Gets U.S. Approval For Weight Loss Drug Liraglutide, With Market Potential Estimated At $127 Million By December 2025

Jefferies on Biocon Hold, TP Rs 360

 16 Feb 2026 09:01 AM

Jefferies on Biocon Hold, TP Rs 360

HSBC maintains buy on Biocon; Cuts target price to ₹445 from ₹455

 16 Feb 2026 09:02 AM

HSBC maintains buy on Biocon; Cuts target price to ₹445 from ₹455

Goldman Sachs maintains neutral on Biocon with a target price of ₹375

 16 Feb 2026 09:03 AM

Goldman Sachs maintains neutral on Biocon with a target price of ₹375